Lilly reports positive results from trial of obesity candidate
Ella Day | August 8, 2025 | News story | Medical Communications, Research and Development | Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a once-daily oral GLP-1 receptor agonist – achieved significant weight loss in adults with obesity or overweight with a related medical condition.
Patients receiving the highest dose of orforglipron (36mg) lost an average of 12.4% of their body weight (approximately 12.3kg), compared to 0.9% (1kg) in the placebo group. Additionally, 59.6% of patients in the 36mg group achieved at least 10% weight loss and 39.6% lost 15% or more.
Orforglipron demonstrated other benefits too. The trial also found improvements in cardiovascular risk markers, including reductions in non-HDL cholesterol, triglycerides, systolic blood pressure and high-sensitivity C-reactive protein, with the latter falling by 47.7% in a pre-specified exploratory analysis.
“Obesity is one of the most pressing global health challenges of our time,” said Kenneth Custer, executive vice president and president of Lilly cardiometabolic health. “With orforglipron, we’re working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management.”
Lilly plans to submit orforglipron for global regulatory review by the end of 2025. Full results from ATTAIN-1 will be presented at the European Association for the Study of Diabetes Annual Meeting in September in Vienna, Austria.
Ella Day
8/8/25
This article featured in: September 2025 – The Pharmafile Brief
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its …
